These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7102502)

  • 41. Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration.
    Arnold TH; Tackett RL; Vallner JJ
    Biopharm Drug Dispos; 1985; 6(4):447-54. PubMed ID: 4084670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation.
    Yang QJ; Si L; Tang H; Sveigaard HH; Chow EC; Pang KS
    Drug Metab Dispos; 2015 Apr; 43(4):631-45. PubMed ID: 25650380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
    Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of the enantiomers of verapamil and norverapamil in serum using coupled achiral-chiral high-performance liquid chromatography.
    Chu YQ; Wainer IW
    J Chromatogr; 1989 Dec; 497():191-200. PubMed ID: 2625456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term oral treatment with high doses of verapamil in lone atrial fibrillation.
    Johansson PA; Olsson SB
    Clin Cardiol; 1984 Mar; 7(3):163-70. PubMed ID: 6705301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.
    Mølgaard H; Bjerregaard P; Jørgensen HS; Klitgaard NA
    Eur J Clin Pharmacol; 1987; 33(5):447-53. PubMed ID: 3428338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
    Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE
    Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences in oral verapamil absorption as a function of time of day.
    Eldon MA; Battle MM; Voigtman RE; Colburn WA
    J Clin Pharmacol; 1989 Nov; 29(11):989-93. PubMed ID: 2600194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical relevance of verapamil plasma levels in stable angina pectoris.
    Frishman W; Kirsten E; Klein M; Pine M; Johnson SM; Hillis LD; Packer M; Kates R
    Am J Cardiol; 1982 Nov; 50(5):1180-4. PubMed ID: 6753558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.
    Hanyok JJ; Chow MS; Kluger J; Izard MW
    J Clin Pharmacol; 1988 Sep; 28(9):831-6. PubMed ID: 3230150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil.
    Gupta SK; Hwang S; Atkinson L; Longstreth J
    J Clin Pharmacol; 1996 Jan; 36(1):25-34. PubMed ID: 8932540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study.
    de Vonderweid U; Benettoni A; Piovan D; Padrini R
    Int J Cardiol; 1984 Nov; 6(5):581-6. PubMed ID: 6500748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia.
    Narang PK; Blumhardt CL; Doran AR; Pickar D
    Clin Pharmacol Ther; 1988 Nov; 44(5):550-7. PubMed ID: 3180637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
    Vlcek J; Macek K; Hůlek P; Brátová M; Fendrich Z
    Arzneimittelforschung; 1995 Feb; 45(2):146-9. PubMed ID: 7710436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.